Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apotransferrin in adults with beta-thalassemia intermedia
NL-OMON55838Phase 2Completed
- Sponsor
- Sanquin Plasma Products
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of apotransferrin in beta-thalassemia intermedia (2 arms), sponsored by Sanquin Plasma Products. Primary endpoint: Hematological response. Started Jun 2019; status: completed.
02
Drugs
apotransferrin
03
Conditions
beta-thalassemia intermedia
Beyond the preview
Go deeper on NL-OMON55838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55838.